Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
Link to record
Permanent link

Direct link
Gedeborg, Rolf, Dr Med Sci. DocentORCID iD iconorcid.org/0000-0002-8850-7863
Alternative names
Publications (10 of 97) Show all publications
Westerberg, M., Gedeborg, R., Garmo, H., Jäderling, F., Stattin, P. & Robinson, D. (2026). Comparison of software vs. cognitive-based fusion-targeted biopsies for prostate cancer diagnosis. BJUI Compass, 7(7), Article ID e70248.
Open this publication in new window or tab >>Comparison of software vs. cognitive-based fusion-targeted biopsies for prostate cancer diagnosis
Show others...
2026 (English)In: BJUI Compass, E-ISSN 2688-4526, Vol. 7, no 7, article id e70248Article in journal (Refereed) Published
Abstract [en]

Objectives: This study aimed to compare the effectiveness of software-based fusion-targeted biopsies (STBx) versus cognitive fusion-targeted biopsies (CogTBx) in detecting prostate cancer (PCa) and clinically significant PCa.

Materials and methods: Men aged 30-85 were included in a target trial emulation if they had undergone a STBx or CogTBx of Prostate Imaging Reporting and Data System (PI-RADS) 3-5 lesions in 2020-2024. Using log-link binary regression models with inverse probability of treatment weighting to adjust for confounding, we estimated the associations between biopsy technique and detection of PCa and clinically significant PCa (Gleason ≥3 + 4 and Gleason ≥4 + 3) by use of adjusted relative risks (aRR) with 95% confidence intervals (CIs) obtained via bootstrapping.

Results: A total of 2092 men who underwent STBx and 7933 men who underwent CogTBx in 2020-2024 were identified in PCBase Xtend. The overall proportion diagnosed with PCa was 64%. STBx detected PCa with a slightly higher frequency (aRR, 1.05; 95% CI, 1.02-1.09), corresponding to an absolute increase of 3.3 percentage points (95% CI 1.2-5.3). The relative risk for detection of Gleason ≥4 + 3 was somewhat larger (aRR, 1.13; 95% CI, 1.03-1.23). The largest relative difference for detection of PCa was observed in PI-RADS 3 lesions (aRR, 1.12; 95% CI, 1.01-1.24), and this pattern became even more apparent when the outcome was restricted to clinically significant PCa.

Conclusions: Software-based fusion-targeted biopsies detected slightly more PCa and clinically significant PCa compared to cognitive fusion-targeted biopsies, particularly in men with PI-RADS 3 lesions. Prioritizing PI-RADS 3 lesions for software-based targeted fusion biopsy could optimize diagnostic effectiveness.

Place, publisher, year, edition, pages
John Wiley & Sons, 2026
Keywords
cognitive-based fusion biopsy, magnetic resonance imaging, prostate cancer, software-based fusion biopsy, targeted biopsy
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-594745 (URN)10.1002/bco2.70248 (DOI)001817099200001 ()42445323 (PubMedID)2-s2.0-105044088108 (Scopus ID)
Funder
Forte, Swedish Research Council for Health, Working Life and Welfare, 2024-01652Swedish Cancer Society, 22 2051ProstatacancerförbundetFuturum - Academy for Health and Care, Jönköping County Council, Sweden, 996182
Available from: 2026-07-31 Created: 2026-07-31 Last updated: 2026-07-31Bibliographically approved
Ventimiglia, E., Westerberg, M., Zaurito, P., Miranda, T. B., Robinson, D., Gedeborg, R. & Garmo, H. (2026). Consequences of different definitions of disease progression in observational studies of men with advanced prostate cancer. Scandinavian journal of urology, 61(1), 22-28
Open this publication in new window or tab >>Consequences of different definitions of disease progression in observational studies of men with advanced prostate cancer
Show others...
2026 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 61, no 1, p. 22-28Article in journal (Refereed) Published
Abstract [en]

Introduction and objectives: Definitions of prostate specific antigen progression for men with prostate cancer on androgen deprivation therapy (ADT) are mainly derived from randomised trials, and their applicability to the clinical practice remains uncertain. This study aimed to assess how different PSA-based definitions of progressions while on ADT affect estimates of progression, treatment initiation, and outcomes in men with prostate cancer.

Methods: Using data from the Prostate Cancer database of Sweden with extended treatments and endpoints data (PCBase Xtend), we identified 3718 men who initiated ADT between 2009 and 2022 and who had longitudinal PSA and treatment data. PSA progression was defined according to four modified guideline-based definitions ranging from the European Association of Urology (EAU) that has the most stringent criteria for progression to our previously used and less stringent definition (PCBase). We analysed cumulative incidence of PSA progression, treatment for castration resistant prostate cancer before and after PSA progression, and prostate cancer-specific mortality, accounting for competing risks.

Results: ADT was prescribed as the primary treatment in 52% of included men. The number of men with PSA progression ranged by definition from 1047 men (28%, EAU) to 2378 men (64%, PCBase) at 10 years after initiation of ADT. Earlier progression was observed with less stringent criteria, with a difference in median time to progression of 3 months (PCBase vs EAU). Despite variation in incidence proportion of PSA progression, the proportion of men treated within 5 years after progression was similar (45-52%), as was prostate cancer-specific mortality (26-27%) across definitions.

Conclusion: While definitions of PSA progression significantly impacted estimated incidence proportion of disease progression, they had limited influence on treatment initiation and long-term mortality. These findings suggest that in the clinical practice, decisions are guided by factors other than formal progression criteria. PSA-based definitions can be useful in observational studies if supported by sensitivity analyses.

Place, publisher, year, edition, pages
MJS Publishing, 2026
Keywords
castration resistant prostate cancer, disease progression, prostate specific antigen, prostate cancer mortality, androgen deprivation therapy
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-587094 (URN)10.2340/sju.v61.45401 (DOI)001694218600001 ()41636457 (PubMedID)2-s2.0-105029523051 (Scopus ID)
Available from: 2026-05-26 Created: 2026-05-26 Last updated: 2026-05-26Bibliographically approved
Scilipoti, P., Callenmark, M., Garmo, H., Stattin, P., Gedeborg, R. & Westerberg, M. (2026). Estimation and Prognostic Role of Prostate-specific Antigen (PSA) Doubling Time After Radical Prostatectomy. European Urology Open Science, 89, 1-9
Open this publication in new window or tab >>Estimation and Prognostic Role of Prostate-specific Antigen (PSA) Doubling Time After Radical Prostatectomy
Show others...
2026 (English)In: European Urology Open Science, ISSN 2666-1691, E-ISSN 2666-1683, Vol. 89, p. 1-9Article in journal (Refereed) Published
Abstract [en]

Background and objective

There are several methods for estimating prostate-specific antigen (PSA) doubling time (DT), and many men exhibit long periods of undetectable PSA below 0.1 ng/ml after radical prostatectomy (RP). We quantified between-method differences in estimated PSA-DT at PSA relapse after RP and evaluated how these differences affect discrimination of prostate cancer (PCa) death.

Methods

Men who underwent RP in 2007–2024 and subsequently developed a PSA relapse, defined as two consecutive values above 0.2 ng/ml, were included. We estimated PSA-DT from the date of the first undetectable PSA after RP until PSA relapse using four methods: (1) all detectable PSAs only, (2) two most recent detectable PSAs, (3) three most recent PSAs (with the third forced to 0.1 ng/ml if ≤0.1 ng/ml), and (4) all PSAs using a missing data approach. Discrimination of 10-yr PCa death was assessed using concordance index (C-index).

Key findings and limitations

A total of 3826 men were included. Median PSA-DT ranged from 4.4 to 8.6 mo, with a wide range in PSA-DT across different estimation methods. All four methods discriminated PCa death to a similar level, with C-index ranging from 0.70 to 0.74, which was slightly lower than the C-index (0.77) for the absolute PSA level at relapse. This study was restricted to men with PSA relapse after RP and may not be generalizable to other patient categories.

Conclusions and clinical implications

PSA-DT after RP was sensitive to the choice of estimation method, and all methods had comparable prognostic value to the last measured PSA level.

Place, publisher, year, edition, pages
Elsevier, 2026
Keywords
Stats Editor:, Doubling time, Detection limit, Prostate-specific antigen, Prostate cancer, Radical prostatectomy
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-592511 (URN)10.1016/j.euros.2026.05.006 (DOI)001781329900001 ()42222855 (PubMedID)2-s2.0-105039292930 (Scopus ID)
Funder
Swedish Research Council, 2022-00544Swedish Cancer Society, 22 2051Forte, Swedish Research Council for Health, Working Life and Welfare, 2024-01652
Available from: 2026-06-26 Created: 2026-06-26 Last updated: 2026-06-26Bibliographically approved
Ventimiglia, E., Garmo, H., Gedeborg, R., Ahlberg, M., Galdieri, A., Orrason, A. W., . . . Robinson, D. (2026). Extent of prostate cancer cases not registered in The National Cancer Register of Sweden and consequences for estimates of prostate cancer incidence and mortality [Letter to the editor]. Acta Oncologica, 65, 297-300
Open this publication in new window or tab >>Extent of prostate cancer cases not registered in The National Cancer Register of Sweden and consequences for estimates of prostate cancer incidence and mortality
Show others...
2026 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 65, p. 297-300Article in journal, Letter (Other academic) Published
Place, publisher, year, edition, pages
MJS Publishing, 2026
Keywords
Prostate cancer, registries, incidence, mortality, PSA, ADT
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-592470 (URN)10.2340/ao.v65.45596 (DOI)001786622600001 ()41993029 (PubMedID)2-s2.0-105035821105 (Scopus ID)
Available from: 2026-06-26 Created: 2026-06-26 Last updated: 2026-06-26Bibliographically approved
Zaurito, P., Garmo, H., Gedeborg, R., Ahlberg, M., Carlsson, S., Thellenberg, C., . . . Westerberg, M. (2026). Incidence and prognostic implications of PSA relapse after radical radiotherapy for prostate cancer: a population-based study. BJU International, 137(4), 629-638
Open this publication in new window or tab >>Incidence and prognostic implications of PSA relapse after radical radiotherapy for prostate cancer: a population-based study
Show others...
2026 (English)In: BJU International, ISSN 1464-4096, E-ISSN 1464-410X, Vol. 137, no 4, p. 629-638Article in journal (Refereed) Published
Abstract [en]

Objective

To estimate risk of prostate-specific antigen (PSA) relapse after radical radiotherapy (RT) for prostate cancer (PCa), and risk of PCa death after relapse according to Gleason score and time to relapse.

Patients and Methods

Men in the National Prostate Cancer Register of Sweden who underwent primary radical RT in 2007–2024 were followed until 31 December 2024. Relapse was defined as a PSA level increase of ≥2 ng/mL above nadir (Phoenix criteria). Competing risk cumulative incidence analyses were used to estimate risk of PSA relapse and risk of PCa death after relapse according to Gleason score and time to relapse.

Results

The 10-year risk of relapse in 26 634 men treated with RT was 25% (95% confidence interval [CI] 24–25%). The 10-year risk of PCa death after relapse was 35% (95% CI 33–37%). In men with relapse after >3 years the risk was 18% for Gleason score 6 and 19% for Gleason score 3 + 4, while in men with a relapse within 18 months the risk was 52% for Gleason score 4 + 3 and 75% for Gleason score 9–10. In men with a relapse at 1 year after RT there was a four-fold higher risk of PCa death for men with Gleason score 9–10 compared to men with Gleason score 6 (86% vs 22%). In contrast, in men with a relapse at 10 years after RT there were little differences in risk of PCa death according to Gleason (14% vs 23%).

Conclusion

In this population-based study of RT for PCa, there was a wide range in the estimates of risk of PCa death after relapse in highly granular groups according to Gleason score and time to relapse. Notably, some estimates did not align with the European Association of Urology relapse risk group classification.

Place, publisher, year, edition, pages
John Wiley & Sons, 2026
Keywords
prostate cancer, radical radiotherapy, prostate-specific antigen, relapse, biochemical recurrence, prostate cancer death
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-582325 (URN)10.1111/bju.70148 (DOI)001708869900024 ()41537396 (PubMedID)2-s2.0-105027562129 (Scopus ID)
Funder
Region UppsalaSwedish Cancer Society, 2022-2051
Available from: 2026-03-16 Created: 2026-03-16 Last updated: 2026-03-16Bibliographically approved
Ventimiglia, E., Westerberg, M., Wilberg Orrason, A., Ahlberg, M., Robinson, D., Gedeborg, R., . . . Garmo, H. (2026). Long-term Outcomes in Men with Stable PSA During 5-a Reductase Inhibitor Thera py After Negative Prostate Biopsy: Population-based Study [Letter to the editor]. European Urology Open Science, 89, 72-76
Open this publication in new window or tab >>Long-term Outcomes in Men with Stable PSA During 5-a Reductase Inhibitor Thera py After Negative Prostate Biopsy: Population-based Study
Show others...
2026 (English)In: European Urology Open Science, ISSN 2666-1691, E-ISSN 2666-1683, Vol. 89, p. 72-76Article in journal, Letter (Refereed) Published
Abstract [en]

Evidence on long-term outcomes after a negative biopsy, particularly prostate cancer mortality, remains limited, and optimal follow-up strategies are unclear. This nationwide population-based study assessed whether prostate-specific antigen (PSA) decline or stability during 5-a reductase inhibitor (5-ARI) therapy after a negative biopsy identifies men at very low risk of prostate cancer and prostate cancer death. Using Prostate Cancer data Base Sweden (PCBaSe Xtend), we identified men with longitudinal PSA and biopsy data who had at least one negative prostate biopsy between 2007 and 2018 and who initiated 5-ARI therapy with defined exposure and adherence criteria. PSA change during the first 2 yr of treatment was evaluated using PSA velocity and classified as stable or increasing. Follow-up started 2 yr after treatment initiation. Among 1248 men, 901 had stable PSA and 347 had increasing PSA. After 10 yr, the cumulative incidence proportion of prostate cancer was 8.3% (95% confidence interval [CI] = 6.0-12%) in men with stable PSA and 18% (95% CI = 13-24%) in men with increasing PSA; most cancers in men with stable PSA were low grade. Prostate cancer mortality was very low among men with stable PSA (standardized mortality ratio [SMR] = 0.19; 95% CI = 0.04-0.56) and higher in men with increasing PSA (SMR = 1.20; 95% CI = 0.52-2.37. Stable PSA during 5-ARI therapy after a negative biopsy was associated with very low prostate cancer mortality; whether this should influence PSA surveillance intensity requires further study.

(c) 2026 The Author(s).

Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creative

Place, publisher, year, edition, pages
Elsevier, 2026
Keywords
5-ARI, Prostate biopsy, Prostate cancer, PSA, Screening
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-593794 (URN)10.1016/j.euros.2026.05.015 (DOI)001798526500001 ()42318006 (PubMedID)2-s2.0-105041678663 (Scopus ID)
Available from: 2026-07-10 Created: 2026-07-10 Last updated: 2026-07-10Bibliographically approved
Ventimiglia, E., Gedeborg, R., Westerberg, M., Zaurito, P., Jäderling, F., Stattin, P. & Garmo, H. (2026). Nationwide population-based longitudinal data on magnetic resonance imaging of the prostate and subsequent prostate biopsy results. Scandinavian journal of urology, 61(1), 64-71
Open this publication in new window or tab >>Nationwide population-based longitudinal data on magnetic resonance imaging of the prostate and subsequent prostate biopsy results
Show others...
2026 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 61, no 1, p. 64-71Article in journal (Refereed) Published
Abstract [en]

Background and aim: Magnetic resonance imaging (MRI) is crucial for prostate cancer (Pca) diagnosis, risk stratification, and treatment planning. However, large-scale observational studies require structured MRI data, which are often only obtainable from free-text reports. We aimed to extract information from narrative prostate MRI reports and to describe subsequent biopsy outcomes in a nationwide population-based cohort.

Methods: We identified 108,361 prostate MRI examinations in Prostate Cancer database Sweden with extended treatments and endpoints data (PCBase Xtend) performed in 2015-2023. A rule-based text recognition algorithm was created and used to extract Prostate Imaging Reporting and Data System (PI-RADS) score and prostate volume from free-text MRI reports. Extracted data were validated against manually extracted information in the National Prostate Cancer Register (NPCR). We examined biopsy rates and Gleason score according to PI-RADS, Prostate Specific Antigen (PSA) density, and calendar year.

Results: The proportion of reports with identifiable PI-RADS scores increased from 38% in 2015-2016 to 83% in 2022-2023, with excellent agreement with NPCR data (correlation coefficient r = 0.94). Extracted prostate volumes correlated well with those in NPCR (r = 0.88). Biopsy rates decreased for PI-RADS 3 lesions over time, particularly in men with PSA density < 0.15 ng/ml/ml, while the proportion of men with PI-RADS 5 lesions who underwent biopsy increased. Almost all prostate cancers in men with PI-RADS 3 lesions were Gleason 6 or 7 (3+4). Gleason 9-10 was almost exclusively found in PI-RADS 5 lesions.

Conclusions: Automated extraction of information from unstructured MRI reports is feasible and accurate. The observed temporal trends reflecting increasing quality and standardization of prostate MRI support its use in large-scale epidemiological research.

Place, publisher, year, edition, pages
MJS Publishing, 2026
Keywords
prostate cancer, prostate MRI, PIRADS, prostate biopsy, PSA density
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-584189 (URN)10.2340/sju.v61.45540 (DOI)001729826100003 ()41879676 (PubMedID)2-s2.0-105034376879 (Scopus ID)
Available from: 2026-04-13 Created: 2026-04-13 Last updated: 2026-04-13Bibliographically approved
Lin, E., Garmo, H., Beckmann, K., Bratt, O., Akre, O., Stattin, P. & Gedeborg, R. (2026). Prostate cancer characteristics in fathers and risk of early onset high-risk prostate cancer in sons. International Journal of Cancer, 158(4), 977-983
Open this publication in new window or tab >>Prostate cancer characteristics in fathers and risk of early onset high-risk prostate cancer in sons
Show others...
2026 (English)In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 158, no 4, p. 977-983Article in journal (Refereed) Published
Abstract [en]

A family history of prostate cancer in first-degree relatives is an established risk factor for prostate cancer, but the specific associations between prostate cancer characteristics in fathers and the risk of high-risk prostate cancer in their sons remain unclear. We identified men in Prostate Cancer data Base Sweden whose fathers had been diagnosed with prostate cancer in 1998-2005. We compared the observed number of prostate cancer diagnoses in these men with the expected number in the Swedish male population, estimating standardized incidence ratios (SIR). The median age of the 25,287 included sons of men with prostate cancer was 52 years (interquartile range 47-57 years) at end of follow-up. Their overall risk of a prostate cancer diagnosis was higher if the father had been diagnosed at less than 65 years old (SIR, 4.3, 95% confidence interval [CI], 3.8-5.0), compared with having a father diagnosed when 70 years old or older (SIR, 2.3; 95% CI 1.9-2.8). Sons of fathers diagnosed at less than 65 had a higher risk of Gleason score >= 8 cancers (SIR, 2.3; 95% CI 1.1-4.1) than sons of fathers diagnosed at 70 years old or older (SIR, 1.2; 95% CI 0.4-2.6). Having a father with a Gleason >= 8 cancer was associated with an increased risk for a Gleason >= 8 cancer (SIR, 2.6; 95% CI 1.1-5.1). These population-based results suggest that the father's prostate cancer characteristics should be considered when counseling men on prostate-specific antigen testing and diagnostic strategies.

Place, publisher, year, edition, pages
John Wiley & Sons, 2026
Keywords
cancer characteristics, cohort study, family history, mortality, prostate cancer
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-583054 (URN)10.1002/ijc.70133 (DOI)001566982200001 ()40926501 (PubMedID)2-s2.0-105015446585 (Scopus ID)
Funder
Swedish Cancer Society
Available from: 2026-03-31 Created: 2026-03-31 Last updated: 2026-03-31Bibliographically approved
Galdieri, A., Garmo, H., Gedeborg, R., Ahlberg, M., Wilberg Orrason, A., Ventimiglia, E., . . . Westerberg, M. (2026). Temporal trends in diagnostic work-up, treatment, and mortality in locally advanced prostate cancer in 2016-2024: nationwide, population-based study in Sweden. Acta Oncologica, 65, 282-288
Open this publication in new window or tab >>Temporal trends in diagnostic work-up, treatment, and mortality in locally advanced prostate cancer in 2016-2024: nationwide, population-based study in Sweden
Show others...
2026 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 65, p. 282-288Article in journal (Refereed) Published
Abstract [en]

Background and purpose: We aimed to describe temporal changes in diagnostic work-up, treatment, and prostate cancer (PCa) mortality in locally advanced PCa in 2016–2024 in Sweden.

Patient/material and methods: Men registered in the National Prostate Cancer Register of Sweden in 2016–2024 with locally advanced PCa; clinical T stage 3–4, no distant metastases, and prostate-specific antigen < 100 ng/ml were included. We computed the proportion of use of prostate magnetic resonance imaging (MRI) before biopsy, radical prostatectomy, radical radiotherapy, androgen deprivation therapy, and abiraterone, and described the trend in PCa mortality across three calendar periods.

Results: During the 9-year study period 7,484 men with locally advanced PCa were identified. Use of MRI before biopsy increased from 3% in 2016 to 73% in 2024. Concomitantly, radical treatment increased from 35% to 48%, entirely due to increased use of radiotherapy. Abiraterone was not used before 2022 but 31% received this treatment in 2024. The 3-year PCa mortality decreased from 8% (95% confidence interval [CI]: 7–9) in 2016–2018 to 6% (95% CI: 4–8) in 2022–2024.

Interpretation: In this nationwide, population-based study of men with locally advanced PCa, the use of MRI before biopsy, radical radiotherapy, and treatment with abiraterone increased over time. These changes coincided with a modest decrease in 3-year PCa mortality.

Place, publisher, year, edition, pages
MJS Publishing, 2026
Keywords
Locally advanced prostate cancer, treatment, mortality, diagnosis, staging
National Category
Cancer and Oncology Urology
Identifiers
urn:nbn:se:uu:diva-591760 (URN)10.2340/ao.v65.45593 (DOI)001786595300001 ()41983270 (PubMedID)
Available from: 2026-06-23 Created: 2026-06-23 Last updated: 2026-06-23Bibliographically approved
Zaurito, P., Gedeborg, R., Garmo, H., Ventimiglia, E., Ahlberg, M., Stattin, P. & Westerberg, M. (2026). Uptake of doublet and triplet therapy for men with de novo metastatic castration-sensitive prostate cancer. Population-based study. Scandinavian journal of urology, 61, 51-57
Open this publication in new window or tab >>Uptake of doublet and triplet therapy for men with de novo metastatic castration-sensitive prostate cancer. Population-based study
Show others...
2026 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 61, p. 51-57Article in journal (Refereed) Published
Abstract [en]

Purpose: In randomised clinical trials, doublet and triplet therapy improved survival compared to standard androgen deprivation therapy (ADT) in men with de novo metastatic castration-sensitive prostate cancer (mCSPC). Guidelines recommend doublet therapy since 2020 and triplet therapy since 2022. The aim of this study was to assess the uptake of upfront doublet and triplet therapy at a population level and assess trends in survival for all men with mCSPC.

Methods: We included men registered with de novo mCSPC in 2016-2024 in the National Prostate Cancer Register of Sweden. We estimated the annual proportion of men with de novo mCSPC who upfront received doublet therapy (ADT plus androgen receptor pathway inhibitor [ARPI] or docetaxel) or triplet therapy (ADT plus docetaxel and ARPI). Kaplan-Meier curves were used to estimate 3-year overall survival.

Results: In 9294 men diagnosed with de novo mCSPC, the use of upfront doublet therapy increased from 19% in 2016 to 66% in 2024, and the use of triplet therapy rose from 4% in 2021 to 17% in 2024. Uptake was highest among men below age 65 years, of whom 46% received doublet and 48% received triplet therapy in 2024. Three-year survival increased from 51%(95%CI: 49-52%) in 2016-2018 to 61%(95%CI: 58-64%) in 2022-2024. Among men below age 65, survival increased from 69% (95% CI: 65-73) in 2019-2021 to 77% (95% CI: 71-84) in 2022-2024.

Conclusions: The uptake of doublet and triplet therapy increased substantially during the study period, in particular among men below age 65. In parallel, 3-year overall survival increased in all men diagnosed with de novo mCSPC. These data provide support for the benefit of upfront doublet or triplet therapy in clinical practice.

Place, publisher, year, edition, pages
MJS Publishing, 2026
Keywords
metastatic prostate cancer, doublet therapy, triplet therapy, androgen deprivation therapy, chemotherapy, androgen receptor pathway inhibitor
National Category
Urology Surgery
Identifiers
urn:nbn:se:uu:diva-584179 (URN)10.2340/sju.v61.45652 (DOI)001729826100002 ()41842888 (PubMedID)2-s2.0-105033690202 (Scopus ID)
Funder
Swedish Cancer Society, 19 00 30Region UppsalaUppsala University
Available from: 2026-04-13 Created: 2026-04-13 Last updated: 2026-04-13Bibliographically approved
Projects
Population-based studies in Prostate Cancer data Base Sweden (PCBaSe) EXTenD. Life expectancy and longterm effects of screening and treatment of prostate cancer in older men [2022-00544_VR]; Uppsala University; Publications
Westerberg, M., Gedeborg, R., Garmo, H., Jäderling, F., Stattin, P. & Robinson, D. (2026). Comparison of software vs. cognitive-based fusion-targeted biopsies for prostate cancer diagnosis. BJUI Compass, 7(7), Article ID e70248. Scilipoti, P., Callenmark, M., Garmo, H., Stattin, P., Gedeborg, R. & Westerberg, M. (2026). Estimation and Prognostic Role of Prostate-specific Antigen (PSA) Doubling Time After Radical Prostatectomy. European Urology Open Science, 89, 1-9Zaurito, P., Garmo, H., Gedeborg, R., Ahlberg, M., Carlsson, S., Thellenberg, C., . . . Westerberg, M. (2026). Incidence and prognostic implications of PSA relapse after radical radiotherapy for prostate cancer: a population-based study. BJU International, 137(4), 629-638Galdieri, A., Garmo, H., Gedeborg, R., Ahlberg, M., Wilberg Orrason, A., Ventimiglia, E., . . . Westerberg, M. (2026). Temporal trends in diagnostic work-up, treatment, and mortality in locally advanced prostate cancer in 2016-2024: nationwide, population-based study in Sweden. Acta Oncologica, 65, 282-288Zaurito, P., Gedeborg, R., Garmo, H., Ventimiglia, E., Ahlberg, M., Stattin, P. & Westerberg, M. (2026). Uptake of doublet and triplet therapy for men with de novo metastatic castration-sensitive prostate cancer. Population-based study. Scandinavian journal of urology, 61, 51-57Zaurito, P., Westerberg, M., Garmo, H., Gedeborg, R., Ventimiglia, E., Wilberg Orrason, A., . . . Robinson, D. (2026). Urinary tract events after radical radiotherapy (RT) for prostate cancer according to pre-RT International Prostate Symptom Score. BJU International, 137(1), 103-111Ventimiglia, E., Gedeborg, R., Orrason, A. W., Zaurito, P., Garmo, H., Stattin, P. & Westerberg, M. (2025). A comparison of comorbidity indices and estimates of life expectancy for men with prostate cancer [Letter to the editor]. Scandinavian journal of urology, 60, 105-107Lin, E., Garmo, H., Beckmann, K., Bratt, O., Stattin, P. & Gedeborg, R. (2025). Family History of Early Onset or Lethal Prostate Cancer and the Risk of Prostate Cancer Death in Sweden. Cancer Epidemiology, Biomarkers and Prevention, 34(9), 1585-1592Westerberg, M., Garmo, H., Bonnedahl, J., Eriksson, M. H., Robinson, D., Stattin, P. & Gedeborg, R. (2025). Optimised comorbidity indices can reflect patient performance status in register based studies of prostate cancer. Scientific Reports, 15(1), Article ID 44645. Zaurito, P., Garmo, H., Gedeborg, R., Ahlberg, M., Orrason, A. W., Styrke, J., . . . Westerberg, M. (2025). Prostate cancer incidence in Sweden before, during and after the COVID-19 pandemic. Population-based study [Letter to the editor]. Scandinavian journal of urology, 60, 93-96
PCBaSe Xtend; Pathfinder project for enrichment of a research database with individual-level healthcare data [2024-01652_Forte]; Uppsala University; Publications
Scilipoti, P., Callenmark, M., Garmo, H., Stattin, P., Gedeborg, R. & Westerberg, M. (2026). Estimation and Prognostic Role of Prostate-specific Antigen (PSA) Doubling Time After Radical Prostatectomy. European Urology Open Science, 89, 1-9Galdieri, A., Garmo, H., Gedeborg, R., Ahlberg, M., Wilberg Orrason, A., Ventimiglia, E., . . . Westerberg, M. (2026). Temporal trends in diagnostic work-up, treatment, and mortality in locally advanced prostate cancer in 2016-2024: nationwide, population-based study in Sweden. Acta Oncologica, 65, 282-288
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-8850-7863

Search in DiVA

Show all publications